Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase Between 2014 and 2017’.

HOME
>
論文・技術情報
>
Comment on ‘Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron(III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase Between 2014 and 2017’.

アブストラクト
ジャーナル名	Drug safety
投稿日	2019/4/3
投稿者	Schaffalitzky de Muckadell, Philip; Strom, Claes Christian
組織名	Pharmacosmos A/S, Medical Affairs, Holbaek, Denmark.;Pharmacosmos A/S, Medical Affairs, Holbaek, Denmark. CCS@pharmacosmos.com.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/30937852/